Monoamine transporters: Vulnerable and vital doorkeepers

Progress in Molecular Biology and Translational Science

Volumn 98, Issue C, 2011, Pages 1-46

  Lin, Zhicheng ^a   Canales, Juan J ^b   Björgvinsson, Thrstur ^a   Thomsen, Morgane ^a   Qu, Hong ^c   Liu, Qing Rong ^d   Torres, Gonzalo E ^e   Caine, S Barak ^a  

^a MCLEAN HOSPITAL   (United States)

^b UNIVERSITY OF CANTERBURY   (New Zealand)

^c PEKING UNIVERSITY   (China)

^d NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^e UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 78650869519     PISSN: 18771173     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-385506-0.00001-6     Document Type: Chapter

References (353)

1. S.G. Amara, and M.J. Kuhar Neurotransmitter transporters: recent progress Annu Rev Neurosci 16 1993 73 93
2. S.Z. Langer, and A.M. Galzin Studies on the serotonin transporter in platelets Experientia 44 1988 127 130
3. M.A. Kurian, J. Zhen, S.Y. Cheng, Y. Li, S.R. Mordekar, and P. Jardine Homozygous loss-of-function mutations in the gene encoding the dopamine transporter are associated with infantile parkinsonism-dystonia J Clin Invest 119 2009 1595 1603
4. Y.M. Wang, R.R. Gainetdinov, F. Fumagalli, F. Xu, S.R. Jones, and C.B. Bock Knockout of the vesicular monoamine transporter 2 gene results in neonatal death and supersensitivity to cocaine and amphetamine Neuron 19 1997 1285 1296
5. E.A. Fon, E.N. Pothos, B.C. Sun, N. Killeen, D. Sulzer, and R.H. Edwards Vesicular transport regulates monoamine storage and release but is not essential for amphetamine action Neuron 19 1997 1271 1283
6. N. Takahashi, L.L. Miner, I. Sora, H. Ujike, R.S. Revay, and V. Kostic VMAT2 knockout mice: heterozygotes display reduced amphetamine-conditioned reward, enhanced amphetamine locomotion, and enhanced MPTP toxicity Proc Natl Acad Sci USA 94 1997 9938 9943
7. S.R. Hansson, B.J. Hoffman, and E. Mezey Ontogeny of vesicular monoamine transporter mRNAs VMAT1 and VMAT2. I. The developing rat central nervous system Brain Res Dev Brain Res 110 1998 135 158
8. D.A. Gutman, and M.J. Owens Serotonin and norepinephrine transporter binding profile of SSRIs Essent Psychopharmacol 7 2006 35 41
9. I.M. Anderson Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability J Affect Disord 58 2000 19 36
10. B.W. Dunlop, and C.B. Nemeroff The role of dopamine in the pathophysiology of depression Arch Gen Psychiatry 64 2007 327 337
11. P. Willner Dopaminergic mechanisms in depression and mania S. Watson, Psychopharmacology: the fourth generation of progress On-line ed. 2002 Lippincott Williams & Wilkins New York
12. R.C. Shelton The dual-action hypothesis: does pharmacology matter? J Clin Psychiatry 65 2004 5 10
13. Z. Zhou, J. Zhen, N.K. Karpowich, R.M. Goetz, C.J. Law, and M.E.A. Reith LeuT-desipramine structure reveals how antidepressants block neurotransmitter reuptake Science 317 2007 1390 1393
14. M.E. Thase, and T. Denko Pharmacotherapy of mood disorders Annu Rev Clin Psychol 4 2008 53 91
15. P.L. Delgado How antidepressant help depression: mechanisms of action and clinical response J Clin Psychiatry 65 2004 25 30
16. M. Bauer, T. Bschor, A. Pfennig, P.C. Whybrow, J. Angst, and M. Versiani World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders in primary care World J Biol Psychiatry 8 2007 67 104
17. M. Bauer, P.C. Whybrow, J. Angst, M. Versiani, and H.J. Moller World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, Part 1: acute and continuation treatment of major depressive disorder World J Biol Psychiatry 3 2002 5 43
18. J.D. Amsterdam Selective serotonin reuptake inhibitor in severe and melancholic depression. In: Special issue: supplement: selective serotonin reuptake inhibitors (SSRIs) in depression: a decade of progress J Psychopharmacol 12 1998 S99 S111
19. R. Whale, E.M. Clifford, Z. Bhagwagar, and P.J. Cowen Decreased sensitivity of 5-HT[sub]ID[/sub] receptors in melancholic depression Br J Psychiatry 178 2001 454 457
20. C.G. Lineberry, J.A. Johnston, R.N. Raymond, and B. Samara A fixed-dose (300 mg) efficacy study of bupropion and placebo in depressed outpatients J Clin Psychiatry 51 1990 194 199
21. S. Dhillon, L.P.H. Yang, and M.P. Curran Spotlight on bupropion in major depressive disorder CNS Drugs 22 2008 613 617
22. J. Ananth Clomiparmine: an antiobsessive drug Can J Psychiatry/La Revue canadienne de psychiatrie 31 1986 253 258
23. D. Ackerman, and S. Greenland Multivariate meta-analysis of controlled drug studies for obsessive-compulsive disorder J Clin Psychopharmacol 22 2002 309 317
24. N.A. Fineberg, I. Pampaloni, S. Pallanti, J. Ipser, and D.J. Stein Sustained response versus relapse: the pharmacotherapeutic goal for obessisive-compulsive disorder Int Clin Psychopharmacol 22 2007 313 322
25. D.A. Gellar, J. Biederman, S.E. Stewart, B. Mullin, A. Martin, and T. Spencer Which SSRI? A meta-analysis of pharmacotherapy trials in pediatric obsessive-compulsive disorder Am J Psychiatry 160 2003 1919 1928
26. D.F. Klein Delineation of two drug-responsive anxiety syndromes Psychopharmacologia 5 1964 397 408
27. C.I.P. Bentez, K. Smith, R.G. Vasile, R. Rende, M.O. Edelen, and M.B. Keller Use of benzodiazepines and selective serotonin reuptake inhibitors in middle-aged and older adults with anxiety disorders: a longitudinal and prospective study. In: Special issue: clinical studies for late-life disorders Am J Geriatr Psychiatry 16 2008 5 13
28. S.E. Bruce, R.G. Vasile, R.M. Goisman, C. Salzman, M. Spencer, and J.T. Machan Are benzodiazepines still the medication for patients with panic disorder with or without agoraphobia? Am J Psychiatry 160 2003 1432 1438
29. G.J.H. van der Linden, D.J. Stein, and A.J.L.M. van Balkom The efficacy of the selective serotonin reuptake inhibitors for social anxiety disorders (social phobia): a meta-analysis of randomized controlled trials. In: Special issue: selective serotonin reuptake inhibitors in the anxiety disorders Int Clin Psychopharmacol 15 2002 S15 S23
30. I.M. Anderson, and M.E. Palm Pharmacological treatments for worry: focus on generalized anxiety disorder G.C.L. Davey, A. Wells, Worry and its psychological disorders: theory, assessment and treatment. Wiley, Hoboken, NJ 2006 305 334
31. L.L. Davis, E.C. Frazier, R.B. Williford, and J.M. Newell Long-term pharmacotherapy for post-traumatic stress disorder CNS Drugs 20 2006 465 476
32. D.L. Goldenberg Update on the treatment of fibromyalgia Bull Rheumatoid Disord 53 2004 1 7
33. R. Staud Pharmacological treatment of fibromyalgia syndrome: new developments Drugs 70 2010 1 14
34. U.M. Anderberg, I. Marteinsdottir, and L. Von-Knorring Citalopram in patients with fibromyalgia: a randomized, double-blind, placebo controlled study Eur J Pain 4 2000 27 35
35. B. Evren, C. Evren, and M.H. Guler An open clinical trial of venlafaxine in the treatment of pain, depressive and anxiety symptoms in fibromyalgia Pain Clinic 18 2006 167 173
36. J. Biederman, T.J. Spencer, J.H. Newcorn, H. Gao, D.R. Milton, and P. Feldman Effect of comorbid symptoms of oppositional defiant disorder on responses to atomoxetine in children with ADHD: a meta-analysis of controlled clinical trial data Psychopharmacology 190 2007 31 41
37. J. Caballero, and M.C. Nahata Atomoxetine hydrochloride for the treatment of attention-deficit/hyperactivity disorder Clin TherInt Peer Rev J Drug Ther 25 2003 3065 3083
38. V.S. Bhatara, and R.R. Aparasu Pharmacotherapy with atomoxetine for US children and adolescents Ann Clin Psychiatry 19 2007 175 180
39. M.S. Mazei-Robison, R.S. Couch, R.C. Shelton, M.A. Stein, and R.D. Blakely Sequence variation in the human dopamine transporter gene in children with attention deficit hyperactivity disorder Neuropharmacology 49 2005 724 736
40. D.J.K. Balfour, and D.L. Ridley The effects of nicotine on neural pathways in depression: a factor in nicotine addiction? Pharmacol Biochem Behav 66 2000 79 85
41. S.M. Hall, G.L. Humfleet, V.I. Reus, R.F. Muoz, D.T. Hartz, and R. Maude-Griffin Psychological intervention and antidepressant treatment in smoking cessation Arch Gen Psychiatry 59 2002 929 937
42. T. Kinnunen, L. Henning, and B.L. Nordstrom Smoking cessation in individuals with depression: recommendations for treatment CNS Drugs 11 1999 93 103
43. S.D. Iversen, and L.L. Iversen Dopamine: 50 years in perspective Trends Neurosci 30 2007 188 193
44. S. Ikemoto, and J. Panksepp The role of nucleus accumbens dopamine in motivated behavior: a unifying interpretation with special reference to reward-seeking Brain Res Brain Res Rev 31 1999 6 41
45. C.M. Pennartz, and H.J. Groenewegen Lopes da Silva FH. The nucleus accumbens as a complex of functionally distinct neuronal ensembles: an integration of behavioural, electrophysiological and anatomical data Prog Neurobiol 42 1994 719 761
46. H.J. Groenewegen The basal ganglia and motor control Neural Plast 10 2003 107 120
47. A.M. Graybiel Habits, rituals, and the evaluative brain Annu Rev Neurosci 31 2008 359 387
48. J.K. Seamans, and C.R. Yang The principal features and mechanisms of dopamine modulation in the prefrontal cortex Prog Neurobiol 74 2004 1 58
49. M.C. Ritz, R.J. Lamb, S.R. Goldberg, and M.J. Kuhar Cocaine receptors on dopamine transporters are related to self-administration of cocaine Science 237 1987 1219 1223
50. B.J. Venton, A.T. Seipel, P.E. Phillips, W.C. Wetsel, D. Gitler, and P. Greengard Cocaine increases dopamine release by mobilization of a synapsin-dependent reserve pool J Neurosci 26 2006 3206 3209
51. N.D. Volkow, G.J. Wang, M.W. Fischman, R. Foltin, J.S. Fowler, and D. Franceschi Effects of route of administration on cocaine induced dopamine transporter blockade in the human brain Life Sci 67 2000 1507 1515
52. N. Chen, J. Zhen, and M.E. Reith Mutation of Trp84 and Asp313 of the dopamine transporter reveals similar mode of binding interaction for GBR12909 and benztropine as opposed to cocaine J Neurochem 89 2004 853 864
53. D.E. Dar, C. Mayo, and G.R. Uhl The interaction of methylphenidate and benztropine with the dopamine transporter is different than other substrates and ligands Biochem Pharmacol 70 2005 461 469
54. C.J. Loland, R.I. Desai, M.F. Zou, J. Cao, P. Grundt, and K. Gerstbrein Relationship between conformational changes in the dopamine transporter and cocaine-like subjective effects of uptake inhibitors Mol Pharmacol 73 2008 813 823
55. R.B. Rothman, M.H. Baumann, T.E. Prisinzano, and A.H. Newman Dopamine transport inhibitors based on GBR12909 and benztropine as potential medications to treat cocaine addiction Biochem Pharmacol 75 2008 2 16
56. G. Tanda, A.H. Newman, and J.L. Katz Discovery of drugs to treat cocaine dependence: behavioral and neurochemical effects of atypical dopamine transport inhibitors Adv Pharmacol 57 2009 253 289
57. P.C. Meltzer, O. Kryatova, D.P. Pham-Huu, P. Donovan, and A. Janowsky The synthesis of bivalent 2beta-carbomethoxy-3beta-(3, 4-dichlorophenyl)-8- heterobicyclo[3.2.1]octane s as probes for proximal binding sites on the dopamine and serotonin transporters Bioorg Med Chem 16 2008 1832 1841
58. A. Ferragud, C. Velazquez-Sanchez, V. Hernandez-Rabaza, A. Nacher, V. Merino, and M. Carda A dopamine transport inhibitor with markedly low abuse liability suppresses cocaine self-administration in the rat Psychopharmacology (Berl) 207 2009 281 289
59. C. Velazquez-Sanchez, A. Ferragud, V. Hernandez-Rabaza, A. Nacher, V. Merino, and M. Carda The dopamine uptake inhibitor 3 alpha-[bis(4′- fluorophenyl)metoxy]-tropane reduces cocaine-induced early-gene expression, locomotor activity, and conditioned reward Neuropsychopharmacology 34 2009 2497 2507
60. C. Velazquez-Sanchez, A. Ferragud, J. Murga, M. Carda, and J.J. Canales The high affinity dopamine uptake inhibitor, JHW 007, blocks cocaine-induced reward, locomotor stimulation and sensitization Eur Neuropsychopharmacol 20 2010 501 508
61. R.Y. Moore, A.E. Halaris, and B.E. Jones Serotonin neurons of the midbrain raphe: ascending projections J Comp Neurol 180 1978 417 438
62. A.R. Green Neuropharmacology of 5-hydroxytryptamine Br J Pharmacol 147 2006 S145 152
63. W.E. Fantegrossi, K.S. Murnane, and C.J. Reissig The behavioral pharmacology of hallucinogens Biochem Pharmacol 75 2008 17 33
64. L.L. Howell, and H.L. Kimmel Monoamine transporters and psychostimulant addiction Biochem Pharmacol 75 2008 196 217
65. G.I. Papakostas Tolerability of modern antidepressants J Clin Psychiatry 69 2008 8 13
66. J.F. Cryan, R.J. Valentino, and I. Lucki Assessing substrates underlying the behavioral effects of antidepressants using the modified rat forced swimming test Neurosci Biobehav Rev 29 2005 547 569
67. F. Petty, L.L. Davis, D. Kabel, and G.L. Kramer Serotonin dysfunction disorders: a behavioral neurochemistry perspective J Clin Psychiatry 57 1996 11 16
68. P. Skolnick, P. Popik, A. Janowsky, B. Beer, and A.S. Lippa Antidepressant-like actions of DOV 21, 947: a "triple" reuptake inhibitor Eur J Pharmacol 461 2003 99 104
69. P. Popik, M. Krawczyk, K. Golembiowska, G. Nowak, A. Janowsky, and P. Skolnick Pharmacological profile of the "triple" monoamine neurotransmitter uptake inhibitor, DOV 102, 677 Cell Mol Neurobiol 26 2006 857 873
70. Z. Chen, J. Yang, and A. Tobak Designing new treatments for depression and anxiety Drugs 11 2008 189 197
71. L.C. Daws Unfaithful neurotransmitter transporters: focus on serotonin uptake and implications for antidepressant efficacy Pharmacol Ther 121 2009 89 99
72. R.D. Spealman Noradrenergic involvement in the discriminative stimulus effects of cocaine in squirrel monkeys J Pharmacol Exp Ther 275 1995 53 62
73. D.M. Platt, J.K. Rowlett, and R.D. Spealman Noradrenergic mechanisms in cocaine-induced reinstatement of drug seeking in squirrel monkeys J Pharmacol Exp Ther 322 2007 894 902
74. M. Sofuoglu, J. Poling, K. Hill, and T. Kosten Atomoxetine attenuates dextroamphetamine effects in humans Am J Drug Alcohol Abuse 35 2009 412 416
75. J.M. Trigo, T. Renoir, L. Lanfumey, M. Hamon, K.P. Lesch, and P. Robledo 3,4-methylenedioxymethamphetamine self-administration is abolished in serotonin transporter knockout mice Biol Psychiatry 62 2007 669 679
76. M.E. Liechti, C. Baumann, A. Gamma, and F.X. Vollenweider Acute psychological effects of 3, 4-methylenedioxymethamphetamine (MDMA, "Ecstasy") are attenuated by the serotonin uptake inhibitor citalopram Neuropsychopharmacology 22 2000 513 521
77. R.Y. Moore, and F.E. Bloom Central catecholamine neuron systems: anatomy and physiology of the norepinephrine and epinephrine systems Annu Rev Neurosci 2 1979 113 168
78. C.W. Berridge, and B.D. Waterhouse The locus coeruleus-noradrenergic system: modulation of behavioral state and state-dependent cognitive processes Brain Res Brain Res Rev 42 2003 33 84
79. K.J. Ressler, and C.B. Nemeroff Role of norepinephrine in the pathophysiology and treatment of mood disorders Biol Psychiatry 46 1999 1219 1233
80. C. Tsigos, and G.P. Chrousos Hypothalamic-pituitary-adrenal axis, neuroendocrine factors and stress J Psychosom Res 53 2002 865 871
81. G.P. Chrousos Stress and disorders of the stress system Nat Rev Endocrinol 5 2009 374 381
82. A.J. Dunn, and A.H. Swiergiel The role of corticotropin-releasing factor and noradrenaline in stress-related responses, and the inter-relationships between the two systems Eur J Pharmacol 583 2008 186 193
83. J. Andersen, A.S. Kristensen, B. Bang-Andersen, and K. Stromgaard Recent advances in the understanding of the interaction of antidepressant drugs with serotonin and norepinephrine transporters Chem Commun (Camb) 7 2009 3677 3692
84. A. Harkin, J.P. Kelly, M. McNamara, T.J. Connor, K. Dredge, and A. Redmond Activity and onset of action of reboxetine and effect of combination with sertraline in an animal model of depression Eur J Pharmacol 364 1999 123 132
85. T.J. Connor, P. Kelliher, A. Harkin, J.P. Kelly, and B.E. Leonard Reboxetine attenuates forced swim test-induced behavioural and neurochemical alterations in the rat Eur J Pharmacol 379 1999 125 133
86. J.F. Cryan, M.E. Page, and I. Lucki Noradrenergic lesions differentially alter the antidepressant-like effects of reboxetine in a modified forced swim test Eur J Pharmacol 436 2002 197 205
87. R. Rygula, N. Abumaria, U. Havemann-Reinecke, E. Ruther, C. Hiemke, and G. Zernig Pharmacological validation of a chronic social stress model of depression in rats: effects of reboxetine, haloperidol and diazepam Behav Pharmacol 19 2008 183 196
88. M.K. Hahn, A. Steele, R.S. Couch, M.A. Stein, and J.J. Krueger Novel and functional norepinephrine transporter protein variants identified in attention-deficit hyperactivity disorder Neuropharmacology 57 2009 694 701
89. Y.P. Liu, Y.L. Lin, C.H. Chuang, Y.C. Kao, S.T. Chang, and C.S. Tung Alpha adrenergic modulation on effects of norepinephrine transporter inhibitor reboxetine in five-choice serial reaction time task J Biomed Sci 16 2009 72
90. E.S. Robinson, D.M. Eagle, A.C. Mar, A. Bari, G. Banerjee, and X. Jiang Similar effects of the selective noradrenaline reuptake inhibitor atomoxetine on three distinct forms of impulsivity in the rat Neuropsychopharmacology 33 2008 1028 1037
91. L.L. Liu, J. Yang, G.F. Lei, G.J. Wang, Y.W. Wang, and R.P. Sun Atomoxetine increases histamine release and improves learning deficits in an animal model of attention-deficit hyperactivity disorder: the spontaneously hypertensive rat Basic Clin Pharmacol Toxicol 102 2008 527 532
92. B. Vaughan, J. Fegert, and C.J. Kratochvil Update on atomoxetine in the treatment of attention-deficit/hyperactivity disorder Expert Opin Pharmacother 10 2009 669 676
93. J.M. Brown, G.R. Hanson, and A.E. Fleckenstein Regulation of the vesicular monoamine transporter-2: a novel mechanism for cocaine and other psychostimulants J Pharmacol Exp Ther 296 2001 762 767
94. E.L. Riddle, M.K. Topham, J.W. Haycock, G.R. Hanson, and A.E. Fleckenstein Differential trafficking of the vesicular monoamine transporter-2 by methamphetamine and cocaine Eur J Pharmacol 449 2002 71 74
95. S.J. Farnsworth, T.J. Volz, G.R. Hanson, and A.E. Fleckenstein Cocaine alters vesicular dopamine sequestration and potassium-stimulated dopamine release: the role of D2 receptor activation J Pharmacol Exp Ther 328 2009 807 812
96. D. Sulzer, T.K. Chen, Y.Y. Lau, H. Kristensen, S. Rayport, and A. Ewing Amphetamine redistributes dopamine from synaptic vesicles to the cytosol and promotes reverse transport J Neurosci 15 1995 4102 4108
97. J.P. Hansen, E.L. Riddle, V. Sandoval, J.M. Brown, J.W. Gibb, and G.R. Hanson Methylenedioxymethamphetamine decreases plasmalemmal and vesicular dopamine transport: mechanisms and implications for neurotoxicity J Pharmacol Exp Ther 300 2002 1093 1100
98. M. Bortolato, K. Chen, and J.C. Shih Monoamine oxidase inactivation: from pathophysiology to therapeutics Adv Drug Deliv Rev 60 2008 1527 1533
99. K. Wimalasena Vesicular monoamine transporters: structure-function, pharmacology, and medicinal chemistry Med Res Rev 2010 10.1002/med.20187
100. 2 dependent neurotransmitter transporters Nature 437 2005 215 223
101. J. Guastella, N. Nelson, H. Nelson, L. Czyzyk, S. Keynan, and M.C. Miedel Cloning and expression of a rat brain GABA transporter Science 249 1990 1303 1306
102. H. Nelson, S. Mandiyan, and N. Nelson Cloning of the human brain GABA transporter FEBS Lett 269 1990 181 184
103. T. Pacholczyk, R.D. Blakely, and S.G. Amara Expression cloning of a cocaine- and antidepressant-sensitive human noradrenaline transporter Nature 350 1991 350 354
104. J.E. Kilty, D. Lorang, and S.G. Amara Cloning and expression of a cocaine-sensitive rat dopamine transporter Science 254 1991 578 579
105. S. Shimada, S. Kitayama, C.L. Lin, A. Patel, E. Nanthakumar, and P. Gregor Cloning and expression of a cocaine-sensitive dopamine transporter complementary DNA Science 254 1991 576 578
106. B.J. Hoffman, E. Mezey, and M.J. Brownstein Cloning of a serotonin transporter affected by antidepressants Science 254 1991 579 580
107. J.D. Erickson, L.E. Eiden, and B.J. Hoffman Expression cloning of a reserpine-sensitive vesicular monoamine transporter Proc Natl Acad Sci USA 89 1992 10993 10997
108. Y. Liu, D. Peter, A. Roghani, S. Schuldiner, G.G. Priv, and D. Eisenberg A cDNA that suppresses MPP+ toxicity encodes a vesicular amine transporter Cell 70 1992 539 551
109. S. Sarker, R. Weissensteiner, I. Steiner, H.H. Sitte, G.F. Ecker, and M. Freissmuth The high-affinity binding site for tricyclic antidepressants resides in the outer vestibule of the serotonin transporter Mol Pharmacol 78 2010 1026 1035
110. C.I. Wang, and R.J. Lewis Emerging structure-function relationships defining monoamine NSS transporter substrate and ligand affinity Biochem Pharmacol 79 2010 1083 1091
111. L. Celik, S. Sinning, K. Severinsen, C.G. Hansen, M.S. Møller, and M. Bols Binding of serotonin to the human serotonin transporter. Molecular modeling and experimental validation J Am Chem Soc 130 2008 3853 3865
112. A.W. Ravna, M. Jaronczyk, and I. Sylte A homology model of SERT based on the LeuTAa template Bioorg Med Chem Lett 16 2006 5594 5597
113. Z. Zhou, J. Zhen, N.K. Karpowich, R.M. Goetz, C.J. Law, and M.E. Reith LeuT-desipramine structure reveals how antidepressants block neurotransmitter reuptake Science 317 2007 1390 1393
114. K.W. Kaufmann, E.S. Dawson, L.K. Henry, J.R. Field, R.D. Blakely, and J. Meiler Structural determinants of species-selective substrate recognition in human and Drosophila serotonin transporters revealed through computational docking studies Proteins 74 2009 630 642
115. M. Indarte, J.D. Madura, and C.K. Surratt Dopamine transporter comparative molecular modeling and binding site prediction using the LeuT(Aa) leucine transporter as a template Proteins 70 2008 1033 1046
116. P.C. Gedeon, M. Indarte, C.K. Surratt, and J.D. Madura Molecular dynamics of leucine and dopamine transporter proteins in a model cell membrane lipid bilayer Proteins 78 2010 797 811
117. F.A. Paczkowski, I.A. Sharpe, S. Dutertre, and R.J. Lewis chi-Conotoxin and tricyclic antidepressant interactions at the norepinephrine transporter define a new transporter model J Biol Chem 282 2007 17837 17844
118. L.K. Henry, E.M. Adkins, Q. Han, and R.D. Blakely Serotonin and cocaine-sensitive inactivation of human serotonin transporters by methanethiosulfonates targeted to transmembrane domain I J Biol Chem 278 2003 37052 37063
119. L.K. Henry, J.R. Field, E.M. Adkins, M.L. Parnas, R.A. Vaughan, and M.F. Zou Tyr-95 and Ile-172 in transmembrane segments 1 and 3 of human serotonin transporters interact to establish high affinity recognition of antidepressants J Biol Chem 281 2006 2012 2023
120. J.R. Field, L.K. Henry, and R.D. Blakely Transmembrane domain 6 of the human serotonin transporter contributes to an aqueously accessible binding pocket for serotonin and the psychostimulant 3,4-methylene dioxymethamphetamine J Biol Chem 285 2010 11270 11280
121. J.G. Chen, A. Sachpatzidis, and G. Rudnick The third transmembrane domain of the serotonin transporter contains residues associated with substrate and cocaine binding J Biol Chem 272 1997 28321 28327
122. E. Zomot, A. Bendahan, M. Quick, Y. Zhao, J.A. Javitch, and B.I. Kanner Mechanism of chloride interaction with neurotransmitter:sodium symporters Nature 449 2007 726 730
123. L.R. Forrest, S. Tavoulari, Y.W. Zhang, G. Rudnick, and B. Honig Identification of a chloride ion binding site in Na+/Cl -dependent transporters Proc Natl Acad Sci USA 104 2007 12761 12766
124. S. Tavoulari, L.R. Forrest, and G. Rudnick Fluoxetine (Prozac) binding to serotonin transporter is modulated by chloride and conformational changes J Neurosci 29 2009 9635 9643
125. K. Erreger, C. Grewer, J.A. Javitch, and A. Galli Currents in response to rapid concentration jumps of amphetamine uncover novel aspects of human dopamine transporter function J Neurosci 28 2008 976 989
126. H.E. Milner, R. Beliveau, and S.M. Jarvis The in situ size of the dopamine transporter is a tetramer as estimated by radiation inactivation Biochim Biophys Acta 1190 1994 185 187
127. J.A. Schmid, P. Scholze, O. Kudlacek, M. Freissmuth, E.A. Singer, and H.H. Sitte Oligomerization of the human serotonin transporter and of the rat GABA transporter 1 visualized by fluorescence resonance energy transfer microscopy in living cells J Biol Chem 276 2001 3805 3810
128. H. Hastrup, A. Karlin, and J.A. Javitch Symmetrical dimer of the human dopamine transporter revealed by cross-linking Cys-306 at the extracellular end of the sixth transmembrane segment Proc Natl Acad Sci USA 98 2001 10055 10060
129. G.E. Torres, A. Carneiro, K. Seamans, C. Fiorentini, A. Sweeney, and W.D. Yao Oligomerization and trafficking of the human dopamine transporter. Mutational analysis identifies critical domains important for the functional expression of the transporter J Biol Chem 278 2003 2731 2739
130. H. Hastrup, N. Sen, and J.A. Javitch The human dopamine transporter forms a tetramer in the plasma membrane: cross-linking of a cysteine in the fourth transmembrane segment is sensitive to cocaine analogs J Biol Chem 278 2003 45045 45048
131. T. Sorkina, S. Doolen, E. Galperin, N.R. Zahniser, and A. Sorkin Oligomerization of dopamine transporters visualized in living cells by fluorescence resonance energy transfer microscopy J Biol Chem 278 2003 28274 28283
132. H.H. Sitte, H. Farhan, and J.A. Javitch Sodium-dependent neurotransmitter transporters: oligomerization as a determinant of transporter function and trafficking Mol Interv 4 2004 38 47
133. S. Seidel, E.A. Singer, H. Just, H. Farhan, P. Scholze, and O. Kudlacek Amphetamines take two to tango: an oligomer-based counter-transport model of neurotransmitter transport explores the amphetamine action Mol Pharmacol 67 2005 140 151
134. L.H. Miner, H.P. Jedema, F.W. Moore, R.D. Blakely, A.A. Grace, and S.R. Sesack Chronic stress increases the plasmalemmal distribution of the norepinephrine transporter and the coexpression of tyrosine hydroxylase in norepinephrine axons in the prefrontal cortex J Neurosci 26 2006 1571 1578
135. M.J. Nirenberg, R.A. Vaughan, G.R. Uhl, M.J. Kuhar, and V.M. Pickel The dopamine transporter is localized to dendritic and axonal plasma membranes of nigrostriatal dopaminergic neurons J Neurosci 16 1996 436 447
136. F.C. Zhou, J.H. Tao-Cheng, L. Segu, T. Patel, and Y. Wang Serotonin transporters are located on the axons beyond the synaptic junctions: anatomical and functional evidence Brain Res 805 1998 241 254
137. B.T. Chen, and M.E. Rice Novel Ca2+ dependence and time course of somatodendritic dopamine release: substantia nigra versus striatum J Neurosci 21 2001 7841 7847
138. M.J. Beckstead, D.K. Grandy, K. Wickman, and J.T. Williams Vesicular dopamine release elicits an inhibitory postsynaptic current in midbrain dopamine neurons Neuron 42 2004 939 946
139. C.P. de Kock, L.N. Cornelisse, N. Burnashev, J.C. Lodder, A.J. Timmerman, and J.J. Couey NMDA receptors trigger neurosecretion of 5-HT within dorsal raphe nucleus of the rat in the absence of action potential firing J Physiol 577 2006 891 905
140. N.R. Zahniser, and A. Sorkin Trafficking of dopamine transporters in psychostimulant actions Semin Cell Dev Biol 20 2009 411 417
141. L.C. Daws, P.D. Callaghan, J.A. Moron, K.M. Kahlig, T.S. Shippenberg, and J.A. Javitch Cocaine increases dopamine uptake and cell surface expression of dopamine transporters Biochem Biophys Res Commun 290 2002 1545 1550
142. K.Y. Little, L.W. Elmer, H. Zhong, J.O. Scheys, and L. Zhang Cocaine induction of dopamine transporter trafficking to the plasma membrane Mol Pharmacol 61 2002 436 445
143. D. Sulzer, M.S. Sonders, N.W. Poulsen, and A. Galli Mechanisms of neurotransmitter release by amphetamines: a review Prog Neurobiol 75 2005 406 433
144. A.E. Fleckenstein, T.J. Volz, E.L. Riddle, J.W. Gibb, and G.R. Hanson New insights into the mechanism of action of amphetamines Annu Rev Pharmacol Toxicol 47 2007 681 698
145. H. Khoshbouei, N. Sen, B. Guptaroy, L. Johnson, D. Lund, and M.E. Gnegy N-terminal phosphorylation of the dopamine transporter is required for amphetamine-induced efflux PLoS Biol 2 2004 387 393
146. L.A. Johnson, B. Guptaroy, D. Lund, S. Shamban, and M.E. Gnegy Regulation of amphetamine-stimulated dopamine efflux by protein kinase C {beta} J Biol Chem 280 2005 10914 10919
147. J.U. Fog, H. Khoshbouei, M. Holy, W.A. Owens, C.B. Vaegter, and N. Sen Calmodulin kinase II interacts with the dopamine transporter C terminus to regulate amphetamine-induced reverse transport Neuron 51 2006 417 429
148. C. Saunders, J.V. Ferrer, L. Shi, J. Chen, G. Merrill, and M.E. Lamb Amphetamine-induced loss of human dopamine transporter activity: an internalization-dependent and cocaine-sensitive mechanism Proc Natl Acad Sci USA 97 2000 6850 6855
149. C.A. Furman, R. Chen, B. Guptaroy, M. Zhang, R.W. Holz, and M. Gnegy Dopamine and amphetamine rapidly increase dopamine transporter trafficking to the surface: live-cell imaging using total internal reflection fluorescence microscopy J Neurosci 29 2009 3328 3336
150. - dependent neurotransmitter transporters: drugs, substrates, presynaptic receptors, and signaling systems Pharmacol Ther 92 2001 21 55
151. G.E. Torres, R.R. Gainetdinov, and M.G. Caron Plasma membrane monoamine transporters: structure, regulation and function Nat Rev Neurosci 4 2003 13 25
152. R.A. Vaughan Phosphorylation and regulation of psychostimulant-sensitive neurotransmitter transporters J Pharmacol Exp Ther 310 2004 1 7
153. H.E. Melikian Neurotransmitter transporter trafficking: endocytosis, recycling, and regulation Pharmacol Ther 104 2004 17 27
154. O.V. Mortensen, and S.G. Amara Dynamic regulation of the dopamine transporter Eur J Pharmacol 479 2003 159 170
155. M.K. Loder, and H.E. Melikian The dopamine transporter constitutively and recycles in a protein kinase C-regulated manner in stably transfected PC12 cell lines J Biol Chem 278 2003 22168 22174
156. G.M. Daniels, and S.G. Amara Regulated trafficking of the human dopamine transporter. Clathrin-mediated internalization and lysosomal degradation in response to phorbol esters J Biol Chem 274 1999 35794 35801
157. C. Granas, J. Ferrer, C.J. Loland, J.A. Javitch, and U. Gether N-terminal truncation of the dopamine transporter abolishes phorbol ester- and substance P receptor-stimulated phosphorylation without impairing transporter internalization J Biol Chem 278 2003 4990 5000
158. K.L. Holton, M.K. Loder, and H.E. Melikian Nonclassical, distinct endocytic signals dictate constitutive and PKC-regulated neurotransmitter transporter internalization Nat Neurosci 8 2005 881 888
159. T. Sorkina, B.R. Hoover, N.R. Zahniser, and A. Sorkin Constitutive and protein kinase C-induced internalization of the dopamine transporter is mediated by a clathrin-dependent mechanism Traffic 6 2005 157 170
160. E. Boudanova, D.M. Navaroli, Z. Stevens, and H.E. Melikian Dopamine transporter endocytic determinants: carboxy terminal residues critical for basal and PKC-stimulated internalization Mol Cell Neurosci 39 2008 211 217
161. T. Sorkina, M. Miranda, K.R. Dionne, B.R. Hoover, N.R. Zahniser, and A. Sorkin RNA interference screen reveals an essential role of Nedd4-2 in dopamine transporter ubiquitination and endocytosis J Neurosci 26 2006 8195 8205
162. T. Sorkina, T.L. Richards, A. Rao, N.R. Zahniser, and A. Sorkin Negative regulation of dopamine transporter endocytosis by membrane-proximal N-terminal residues J Neurosci 29 2009 1361 1374
163. H. Jiang, Q. Jiang, and J. Feng Parkin increases dopamine uptake by enhancing the cell surface expression of dopamine transporter J Biol Chem 279 2004 54380 54386
164. M. Miranda, and A. Sorkin Regulation of receptors and transporters by ubiquitination: new insights into surprisingly similar mechanisms Mol Interv 7 2007 157 167
165. G.E. Torres, W.D. Yao, A.R. Mohn, H. Quan, K.M. Kim, and A.I. Levey Functional interaction between monoamine plasma membrane transporters and the synaptic PDZ domain-containing protein PICK1 Neuron 30 2001 121 124
166. A.M. Carneiro, S.L. Ingram, J.M. Beaulieu, A. Sweeney, S.G. Amara, and S.M. Thomas The multiple LIM domain-containing adaptor protein Hic-5 synaptically colocalizes and interacts with the dopamine transporter J Neurosci 22 2002 7045 7054
167. F.J. Lee, F. Liu, Z.B. Pristupa, and H.B. Niznik Direct binding and functional coupling of alpha-synuclein to the dopamine transporters accelerate dopamine-induced apoptosis FASEB J 15 2001 916 926
168. C. Wersinger, M. Rusnak, and A. Sidhu Modulation of the trafficking of the human serotonin transporter by human alpha-synuclein Eur J Neurosci 24 2006 55 64
169. C. Wersinger, A. Jeannotte, and A. Sidhu Attenuation of the norepinephrine transporter activity and trafficking via interactions with alpha-synuclein Eur J Neurosci 24 2006 3141 3152
170. A.L. Bauman, S. Apparsundaram, S. Ramamoorthy, B.E. Wadzinski, R.A. Vaughan, and R.D. Blakely Cocaine and antidepressant-sensitive biogenic amine transporters exist in regulated complexes with protein phosphatase 2A J Neurosci 20 2000 7571 7578
171. A. Vina-Vilaseca, and A. Sorkin Lysine 63-linked polyubiquitination of the dopamine transporter requires WW3 and WW4 domains of Nedd4-2 and UBE2D ubiquitin-conjugating enzymes J Biol Chem 285 2010 7645 7656
172. D. Marazziti, S. Mandillo, C. Di Pietro, E. Golini, R. Matteoni, and G.P. Tocchini-Valentini GPR37 associates with the dopamine transporter to modulate dopamine uptake and behavioral responses to dopaminergic drugs Proc Natl Acad Sci USA 104 2007 9846 9851
173. A. Moszczynska, J. Saleh, H. Zhang, B. Vukusic, F.J. Lee, and F. Liu Parkin disrupts the alpha-synuclein/dopamine transporter interaction: consequences toward dopamine-induced toxicity J Mol Neurosci 32 2007 217 227
174. F.J. Lee, L. Pei, A. Moszczynska, B. Vukusic, P.J. Fletcher, and F. Liu Dopamine transporter cell surface localization facilitated by a direct interaction with the dopamine D2 receptor EMBO J 26 2007 2127 2136
175. F.J. Lee, L. Pei, and F. Liu Disruption of the dopamine transporter-dopamine D2 receptor interaction in schizophrenia Synapse 63 2009 710 712
176. K.H. Lee, M.Y. Kim, D.H. Kim, and Y.S. Lee Syntaxin 1A and receptor for activated C kinase interact with the N-terminal region of human dopamine transporter Neurochem Res 29 2004 1405 1409
177. F. Binda, C. Dipace, E. Bowton, S.D. Robertson, B.J. Lute, and J.U. Fog Syntaxin 1A interaction with the dopamine transporter promotes amphetamine-induced dopamine efflux Mol Pharmacol 74 2008 1101 1108
178. L.A. Egaa, R.A. Cuevas, T.B. Baust, L.A. Parra, R.K. Leak, and S. Hochendoner Physical and functional interaction between the dopamine transporter and the synaptic vesicle protein synaptogyrin-3 J Neurosci 29 2009 4592 4604
179. R. Chen, C.A. Furman, M. Zhang, M.N. Kim, R.W. Gereau, and M. Leitges Protein kinase Cbeta is a critical regulator of dopamine transporter trafficking and regulates the behavioral response to amphetamine in mice J Pharmacol Exp Ther 328 2009 912 920
180. S. Ramamoorthy, and R.D. Blakely Phosphorylation and sequestration of serotonin transporters differentially modulated by psychostimulants Science 285 1999 763 766
181. M.W. Quick Regulating the conducting states of a mammalian serotonintransporter Neuron 40 2003 537 549
182. M.A. Ciccone, M. Timmons, A. Phillips, and M.W. Quick Calcium/calmodulin-dependent kinase II regulates the interaction between the serotonin transporter and syntaxin 1A Neuropharmacology 55 2008 763 770
183. A.M. Carneiro, and R.D. Blakely Serotonin-, protein kinase C-, and Hic-5-associated redistribution of the platelet serotonin transporter J Biol Chem 281 2006 24769 24780
184. H.K. Mller, O. Wiborg, and J. Haase Subcellular redistribution of the serotonin transporter by secretory carrier membrane protein 2 J Biol Chem 281 2006 28901 28909
185. B. Chanrion, C. Mannoury la Cour, F. Bertaso, M. Lerner-Natoli, M. Freissmuth, and M.J. Millan Physical interaction between the serotonin transporter and neuronal nitric oxide synthase underlies reciprocal modulation of their activity Proc Natl Acad Sci USA 104 2007 8119 8124
186. J.A. Steiner, A.M. Carneiro, J. Wright, H.J. Matthies, H.C. Prasad, and C.K. Nicki cGMP-dependent protein kinase Ialpha associates with the antidepressant-sensitive serotonin transporter and dictates rapid modulation of serotonin uptake Mol Brain 2 2009 26
187. U. Sung, S. Apparsundaram, A. Galli, K.M. Kahlig, V. Savchenko, and S. Schroeter A regulated interaction of syntaxin 1A with the antidepressant- sensitive norepinephrine transporter establishes catecholamine clearance capacity J Neurosci 23 2003 1697 1709
188. U. Sung, J.L. Jennings, A.J. Link, and R.D. Blakely Proteomic analysis of human norepinephrine transporter complexes reveals associations with protein phosphatase 2A anchoring subunit and 14-3-3 proteins Biochem Biophys Res Commun 333 2005 671 678
189. E.A. Cartier, L.A. Parra, T.B. Baust, M. Quiroz, G. Salazar, and V. Faundez A biochemical and functional protein complex involving dopamine synthesis and transport into synaptic vesicles J Biol Chem 285 2010 1957 1966
190. I. Sora, F.S. Hall, A.M. Andrews, M. Itokawa, X.F. Li, and H.B. Wei Molecular mechanisms of cocaine reward: combined dopamine and serotonin transporter knockouts eliminate cocaine place preference Proc Natl Acad Sci USA 98 2001 5300 5305
191. I. Sora, C. Wichems, N. Takahashi, X.F. Li, Z. Zeng, and R. Revay Cocaine reward models: conditioned place preference can be established in dopamine- and in serotonin-transporter knockout mice Proc Natl Acad Sci USA 95 1998 7699 7704
192. R.R. Gainetdinov, S.R. Jones, and M.G. Caron Functional hyperdopaminergia in dopamine transporter knock-out mice Biol Psychiatry 46 1999 303 311
193. R.R. Gainetdinov, W.C. Wetsel, S.R. Jones, E.D. Levin, M. Jaber, and M.G. Caron Role of serotonin in the paradoxical calming effect of psychostimulants on hyperactivity Science 283 1999 397 401
194. J.P. Wisor, S. Nishino, I. Sora, G.H. Uhl, E. Mignot, and D.M. Edgar Dopaminergic role in stimulant-induced wakefulness J Neurosci 21 2001 1787 1794
195. A.N. Mead, B.A. Rocha, D.M. Donovan, and J.L. Katz Intravenous cocaine induced-activity and behavioural sensitization in norepinephrine-, but not dopamine-transporter knockout mice Eur J Neurosci 16 2002 514 520
196. M. Cyr, J.M. Beaulieu, A. Laakso, T.D. Sotnikova, W.D. Yao, and L.M. Bohn Sustained elevation of extracellular dopamine causes motor dysfunction and selective degeneration of striatal GABAergic neurons Proc Natl Acad Sci USA 100 2003 11035 11040
197. P.O. Fernagut, S. Chalon, E. Diguet, D. Guilloteau, F. Tison, and M. Jaber Motor behaviour deficits and their histopathological and functional correlates in the nigrostriatal system of dopamine transporter knockout mice Neuroscience 116 2003 1123 1130
198. N. Hironaka, K. Ikeda, I. Sora, G.R. Uhl, and H. Niki Food-reinforced operant behavior in dopamine transporter knockout mice: enhanced resistance to extinction Ann NY Acad Sci 1025 2004 140 145
199. E. Morice, J.M. Billard, C. Denis, F. Mathieu, C. Betancur, and J. Epelbaum Parallel loss of hippocampal LTD and cognitive flexibility in a genetic model of hyperdopaminergia Neuropsychopharmacology 32 2007 2108 2116
200. M. Thomsen, F.S. Hall, G.R. Uhl, and S.B. Caine Dramatically decreased cocaine self-administration in dopamine but not serotonin transporter knock-out mice J Neurosci 29 2009 1087 1092
201. X. Zhuang, R.S. Oosting, S.R. Jones, R.R. Gainetdinov, G.W. Miller, and M.G. Caron Hyperactivity and impaired response habituation in hyperdopaminergic mice Proc Natl Acad Sci USA 98 2001 1982 1987
202. R.J. Ralph-Williams, M.P. Paulus, X. Zhuang, R. Hen, and M.A. Geyer Valproate attenuates hyperactive and perseverative behaviors in mutant mice with a dysregulated dopamine system Biol Psychiatry 53 2003 352 359
203. K.C. Berridge, J.W. Aldridge, K.R. Houchard, and X. Zhuang Sequential super-stereotypy of an instinctive fixed action pattern in hyper-dopaminergic mutant mice: a model of obsessive compulsive disorder and Tourette's BMC Biol 3 2005 4
204. M.R. Tilley, B. Cagniard, X. Zhuang, D.D. Han, N. Tiao, and H.H. Gu Cocaine reward and locomotion stimulation in mice with reduced dopamine transporter expression BMC Neurosci 8 2007 42
205. S. Pecina, B. Cagniard, K.C. Berridge, J.W. Aldridge, and X. Zhuang Hyperdopaminergic mutant mice have higher "wanting" but not "liking" for sweet rewards J Neurosci 23 2003 9395 9402
206. H.H. Yin, X. Zhuang, and B.W. Balleine Instrumental learning in hyperdopaminergic mice Neurobiol Learn Mem 85 2006 283 288
207. F. Balci, E.A. Ludvig, R. Abner, X. Zhuang, P. Poon, and D. Brunner Motivational effects on interval timing in dopamine transporter (DAT) knockdown mice Brain Res 1325 2010 89 99
208. D.M. Donovan, L.L. Miner, M.P. Perry, R.S. Revay, L.G. Sharpe, and S. Przedborski Cocaine reward and MPTP toxicity: alteration by regional variant dopamine transporter overexpression Brain Res Mol Brain Res 73 1999 37 49
209. A. Salahpour, A.J. Ramsey, I.O. Medvedev, B. Kile, T.D. Sotnikova, and E. Holmstrand Increased amphetamine-induced hyperactivity and reward in mice overexpressing the dopamine transporter Proc Natl Acad Sci USA 105 2008 4405 4410
210. M. Thomsen, D.D. Han, H.H. Gu, and S.B. Caine Lack of cocaine self-administration in mice expressing a cocaine-insensitive dopamine transporter J Pharmacol Exp Ther 331 2009 204 211
211. R. Chen, M.R. Tilley, H. Wei, F. Zhou, F.M. Zhou, and S. Ching Abolished cocaine reward in mice with a cocaine-insensitive dopamine transporter Proc Natl Acad Sci USA 103 2006 9333 9338
212. M.R. Tilley, and H.H. Gu Dopamine transporter inhibition is required for cocaine-induced stereotypy NeuroReport 19 2008 1137 1140
213. M.R. Tilley, B. O'Neill, D.D. Han, and H.H. Gu Cocaine does not produce reward in absence of dopamine transporter inhibition NeuroReport 20 2009 9 12
214. M.A. Fox, C.L. Jensen, P.S. Gallagher, and D.L. Murphy Receptor mediation of exaggerated responses to serotonin-enhancing drugs in serotonin transporter (SERT)-deficient mice Neuropharmacology 53 2007 643 656
215. M.A. Fox, and C.L. Jensen Murphy DL Tramadol and another atypical opioid meperidine have exaggerated serotonin syndrome behavioural effects, but decreased analgesic effects, in genetically deficient serotonin transporter (SERT) mice Int J Neuropsychopharmacol 12 2009 1055 1065
216. A.V. Kalueff, C.L. Jensen, and D.L. Murphy Locomotory patterns, spatiotemporal organization of exploration and spatial memory in serotonin transporter knockout mice Brain Res 1169 2007 87 97
217. A. Holmes, D.L. Murphy, and J.N. Crawley Reduced aggression in mice lacking the serotonin transporter Psychopharmacology (Berl) 161 2002 160 167
218. A. Holmes, R.J. Yang, D.L. Murphy, and J.N. Crawley Evaluation of antidepressant-related behavioral responses in mice lacking the serotonin transporter Neuropsychopharmacology 27 2002 914 923
219. A. Holmes, R.J. Yang, K.P. Lesch, J.N. Crawley, and D.L. Murphy Mice lacking the serotonin transporter exhibit 5-HT(1A) receptor-mediated abnormalities in tests for anxiety-like behavior Neuropsychopharmacology 28 2003 2077 2088
220. S. Zhao, J. Edwards, J. Carroll, L. Wiedholz, R.A. Millstein, and C. Jaing Insertion mutation at the C-terminus of the serotonin transporter disrupts brain serotonin function and emotion-related behaviors in mice Neuroscience 140 2006 321 334
221. A.V. Kalueff, M.A. Fox, P.S. Gallagher, and D.L. Murphy Hypolocomotion, anxiety and serotonin syndrome-like behavior contribute to the complex phenotype of serotonin transporter knockout mice Genes Brain Behav 6 2007 389 400
222. A.V. Kalueff, R.F. Ren-Patterson, and D.L. Murphy The developing use of heterozygous mutant mouse models in brain monoamine transporter research Trends Pharmacol Sci 28 2007 122 127
223. J.D. Olivier, L.A. Jans, G.A. Korte-Bouws, S.M. Korte, P.M. Deen, and A.R. Cools Acute tryptophan depletion dose dependently impairs object memory in serotonin transporter knockout rats Psychopharmacology (Berl) 200 2008 243 254
224. M.T. Perona, S. Waters, F.S. Hall, I. Sora, K.P. Lesch, and D.L. Murphy Animal models of depression in dopamine, serotonin, and norepinephrine transporter knockout mice: prominent effects of dopamine transporter deletions Behav Pharmacol 19 2008 566 574
225. J.R. Homberg, R. van den Bos, E. den Heijer, R. Suer, and E. Cuppen Serotonin transporter dosage modulates long-term decision-making in rat and human Neuropharmacology 55 2008 80 84
226. J.R. Homberg, T. Pattij, M.C. Janssen, E. Ronken, S.F. De Boer, and A.N. Schoffelmeer Serotonin transporter deficiency in rats improves inhibitory control but not behavioural flexibility Eur J Neurosci 26 2007 2066 2073
227. J.R. Homberg, O.J. Schiepers, A.N. Schoffelmeer, E. Cuppen, and L.J. Vanderschuren Acute and constitutive increases in central serotonin levels reduce social play behaviour in peri-adolescent rats Psychopharmacology (Berl) 195 2007 175 182
228. A. Holmes, Q. Lit, D.L. Murphy, E. Gold, and J.N. Crawley Abnormal anxiety-related behavior in serotonin transporter null mutant mice: the influence of genetic background Genes Brain Behav 2 2003 365 380
229. C.L. Wellman, A. Izquierdo, J.E. Garrett, K.P. Martin, J. Carroll, and R. Millstein Impaired stress-coping and fear extinction and abnormal corticolimbic morphology in serotonin transporter knock-out mice J Neurosci 27 2007 684 691
230. J.R. Homberg, S.F. De Boer, H.S. Raaso, J.D. Olivier, M. Verheul, and E. Ronken Adaptations in pre- and postsynaptic 5-HT1A receptor function and cocaine supersensitivity in serotonin transporter knockout rats Psychopharmacology (Berl) 200 2008 367 380
231. J.D. Olivier, L.A. Jans, A. Blokland, N.J. Broers, J.R. Homberg, and B.A. Ellenbroek Serotonin transporter deficiency in rats contributes to impaired object memory Genes Brain Behav 8 2009 829 834
232. K.A. Jennings, M.K. Loder, W.J. Sheward, Q. Pei, R.M. Deacon, and M.A. Benson Increased expression of the 5-HT transporter confers a low-anxiety phenotype linked to decreased 5-HT transmission J Neurosci 26 2006 8955 8964
233. N. Dawson, L. Ferrington, H.J. Olverman, A.J. Harmar, and P.A. Kelly Sex influences the effect of a lifelong increase in serotonin transporter function on cerebral metabolism J Neurosci Res 87 2009 2375 2385
234. F. Xu, R.R. Gainetdinov, W.C. Wetsel, S.R. Jones, L.M. Bohn, and G.W. Miller Mice lacking the norepinephrine transporter are supersensitive to psychostimulants Nat Neurosci 3 2000 465 471
235. M. Dziedzicka-Wasylewska, A. Faron-Gorecka, M. Kusmider, E. Drozdowska, Z. Rogoz, and J. Siwanowicz Effect of antidepressant drugs in mice lacking the norepinephrine transporter Neuropsychopharmacology 31 2006 2424 2432
236. B. Haenisch, A. Bilkei-Gorzo, M.G. Caron, and H. Bonisch Knockout of the norepinephrine transporter and pharmacologically diverse antidepressants prevent behavioral and brain neurotrophin alterations in two chronic stress models of depression J Neurochem 111 2009 403 416
237. L.M. Bohn, F. Xu, R.R. Gainetdinov, and M.G. Caron Potentiated opioid analgesia in norepinephrine transporter knock-out mice J Neurosci 20 2000 9040 9045
238. K.S. Rommelfanger, D. Weinshenker, and G.W. Miller Reduced MPTP toxicity in noradrenaline transporter knockout mice J Neurochem 91 2004 1116 1124
239. R.M. Kaminski, T.S. Shippenberg, J.M. Witkin, and B.A. Rocha Genetic deletion of the norepinephrine transporter decreases vulnerability to seizures Neurosci Lett 382 2005 51 55
240. T.H. Ahern, M.A. Javors, D.A. Eagles, J. Martillotti, H.A. Mitchell, and L.C. Liles The effects of chronic norepinephrine transporter inactivation on seizure susceptibility in mice Neuropsychopharmacology 31 2006 730 738
241. N.R. Keller, A. Diedrich, M. Appalsamy, S. Tuntrakool, S. Lonce, and C. Finney Norepinephrine transporter-deficient mice exhibit excessive tachycardia and elevated blood pressure with wakefulness and activity Circulation 110 2004 1191 1196
242. S. Fukushima, H. Shen, H. Hata, A. Ohara, K. Ohmi, and K. Ikeda Methamphetamine-induced locomotor activity and sensitization in dopamine transporter and vesicular monoamine transporter 2 double mutant mice Psychopharmacology (Berl) 193 2007 55 62
243. F. Fumagalli, R.R. Gainetdinov, Y.M. Wang, K.J. Valenzano, G.W. Miller, and M.G. Caron Increased methamphetamine neurotoxicity in heterozygous vesicular monoamine transporter 2 knock-out mice J Neurosci 19 1999 2424 2431
244. K.V. Savelieva, W.M. Caudle, and G.W. Miller Altered ethanol-associated behaviors in vesicular monoamine transporter heterozygote knockout mice Alcohol 40 2006 87 94
245. R.R. Gainetdinov, F. Fumagalli, Y.M. Wang, S.R. Jones, A.I. Levey, and G.W. Miller Increased MPTP neurotoxicity in vesicular monoamine transporter 2 heterozygote knockout mice J Neurochem 70 1998 1973 1978
246. K.E. Larsen, E.A. Fon, T.G. Hastings, R.H. Edwards, and D. Sulzer Methamphetamine-induced degeneration of dopaminergic neurons involves autophagy and upregulation of dopamine synthesis J Neurosci 22 2002 8951 8960
247. S. Kariya, N. Takahashi, M. Hirano, and S. Ueno Increased vulnerability to L-DOPA toxicity in dopaminergic neurons From VMAT2 heterozygote knockout mice J Mol Neurosci 27 2005 277 279
248. F.S. Hall, I. Sora, and G.R. Uhl Sex-dependent modulation of ethanol consumption in vesicular monoamine transporter 2 (VMAT2) and dopamine transporter (DAT) knockout mice Neuropsychopharmacology 28 2003 620 628
249. M. Fukui, R.M. Rodriguiz, J. Zhou, S.X. Jiang, L.E. Phillips, and M.G. Caron Vmat2 heterozygous mutant mice display a depressive-like phenotype J Neurosci 27 2007 10520 10529
250. K.A. Mooslehner, P.M. Chan, W. Xu, L. Liu, C. Smadja, and T. Humby Mice with very low expression of the vesicular monoamine transporter 2 gene survive into adulthood: potential mouse model for parkinsonism Mol Cell Biol 21 2001 5321 5331
251. T.S. Guillot, K.R. Shepherd, J.R. Richardson, M.Z. Wang, Y. Li, and P.C. Emson Reduced vesicular storage of dopamine exacerbates methamphetamine-induced neurodegeneration and astrogliosis J Neurochem 106 2008 2205 2217
252. R.E. Colebrooke, T. Humby, P.J. Lynch, D.P. McGowan, J. Xia, and P.C. Emson Age-related decline in striatal dopamine content and motor performance occurs in the absence of nigral cell loss in a genetic mouse model of Parkinson's disease Eur J Neurosci 24 2006 2622 2630
253. W.M. Caudle, J.R. Richardson, M.Z. Wang, T.N. Taylor, T.S. Guillot, and A.L. McCormack Reduced vesicular storage of dopamine causes progressive nigrostriatal neurodegeneration J Neurosci 27 2007 8138 8148
254. T.N. Taylor, W.M. Caudle, K.R. Shepherd, A. Noorian, C.R. Jackson, and P.M. Iuvone Nonmotor symptoms of Parkinson's disease revealed in an animal model with reduced monoamine storage capacity J Neurosci 29 2009 8103 8113
255. Z. Lin, and B.K. Madras Human genetics and pharmacology of neurotransmitter transporters Handb Exp Pharmacol 175 2006 327 371
256. G.M. Miller, and B.K. Madras Polymorphisms in the 3′-untranslated region of human and monkey dopamine transporter genes affect reporter gene expression Mol Psychiatry 7 2002 44 55
257. L.K. Jacobsen, J.K. Staley, S.S. Zoghbi, J.P. Seibyl, T.R. Kosten, and R.B. Innis Prediction of dopamine transporter binding availability by genotype: a preliminary report Am J Psychiatry 157 2000 1700 1703
258. E.M. van de Giessen, M.M. de Win, M.W. Tanck, W. van den Brink, F. Baas, and J. Booij Striatal dopamine transporter availability associated with polymorphisms in the dopamine transporter gene SLC6A3 J Nucl Med 50 2009 45 52
259. T.A. Greenwood, and J.R. Kelsoe Promoter and intronic variants affect the transcriptional regulation of the human dopamine transporter gene Genomics 82 2003 511 520
260. M. Hill, R.J. Anney, M. Gill, and Z. Hawi Functional analysis of intron 8 and 3′ UTR variable number of tandem repeats of SLC6A3: differential activity of intron 8 variants Pharmacogenomics J 10 2009 442 447
261. M. Althaus, Y. Groen, A.A. Wijers, R.B. Minderaa, I.P. Kema, and J.D. Dijck Variants of the SLC6A3 (DAT1) polymorphism affect performance monitoring-related cortical evoked potentials that are associated with ADHD Biol Psychol 85 2010 19 32
262. S. Durston, J.A. Fossella, M.J. Mulder, B.J. Casey, T.B. Ziermans, and M.N. Vessaz Dopamine transporter genotype conveys familial risk of attention-deficit/hyperactivity disorder through striatal activation J Am Acad Child Adolesc Psychiatry 47 2008 61 67
263. A.B. Brown, J. Biederman, E.M. Valera, A.E. Doyle, G. Bush, and T. Spencer Effect of dopamine transporter gene (SLC6A3) variation on dorsal anterior cingulate function in attention-deficit/hyperactivity disorder Am J Med Genet B Neuropsychiatr Genet 153B 2010 365 375
264. E.E. Forbes, S.M. Brown, M. Kimak, R.E. Ferrell, S.B. Manuck, and A.R. Hariri Genetic variation in components of dopamine neurotransmission impacts ventral striatal reactivity associated with impulsivity Mol Psychiatry 14 2009 60 70
265. S. Friedel, K. Saar, S. Sauer, A. Dempfle, S. Walitza, and T. Renner Association and linkage of allelic variants of the dopamine transporter gene in ADHD Mol Psychiatry 12 2007 923 933
266. A.J. Bobb, F.X. Castellanos, A.M. Addington, and J.L. Rapoport Molecular genetic studies of ADHD: 1991 to 2004 Am J Med Genet B Neuropsychiatr Genet 132 2005 109 125
267. C.H. Kim, M.K. Hahn, Y. Joung, S.L. Anderson, A.H. Steele, and M.S. Mazei-Robinson A polymorphism in the norepinephrine transporter gene alters promoter activity and is associated with attention-deficit hyperactivity disorder Proc Natl Acad Sci USA 103 2006 19164 19169
268. P. Courtet, P. Baud, M. Abbar, J.P. Boulenger, D. Castelnau, and D. Mouthon Association between violent suicidal behavior and the low activity allele of the serotonin transporter gene Mol Psychiatry 6 2001 338 341
269. S. Ueno, M. Nakamura, M. Mikami, K. Kondoh, H. Ishiguro, and T. Arinami Identification of a novel polymorphism of the human dopamine transporter (DAT1) gene and the significant association with alcoholism Mol Psychiatry 4 1999 552 557
270. M.D. Khnke, A. Batra, W. Kolb, A.M. Khnke, U. Lutz, and S. Schick Association of the dopamine transporter gene with alcoholism Alcohol Alcohol 40 2005 339 342
271. C. Seneviratne, W. Huang, N. Ait-Daoud, M.D. Li, and B.A. Johnson Characterization of a functional polymorphism in the 3′ UTR of SLC6A4 and its association with drinking intensity Alcohol Clin Exp Res 33 2009 332 339
272. Z. Lin, D. Walther, X.Y. Yu, S. Li, T. Drgon, and G.R. Uhl SLC18A2 promoter haplotypes and identification of a novel protective factor against alcoholism Hum Mol Genet 14 2005 1393 1404
273. S.G. Schwab, P.E. Franke, B. Hoefgen, V. Guttenthaler, D. Lichtermann, and M. Trixler Association of DNA polymorphisms in the synaptic vesicular amine transporter gene (SLC18A2) with alcohol and nicotine dependence Neuropsychopharmacology 30 2005 2263 2268
274. D. Quaranta, A. Bizzarro, C. Marra, M.G. Vita, D. Seripa, and A. Pilotto Psychotic symptoms in Alzheimer's disease and 5-HTTLPR polymorphism of the serotonin transporter gene: evidence for an association J Alzheimers Dis 16 2009 173 180
275. P.R. Joyce, P.C. McHugh, K.J. Light, S. Rowe, A.L. Miller, and M.A. Kennedy Relationships between angry-impulsive personality traits and genetic polymorphisms of the dopamine transporter Biol Psychiatry 66 2009 717 721
276. R.E. Urwin, B. Bennetts, B. Wilcken, B. Lampropoulos, P. Beumont, and S. Clarke Anorexia nervosa (restrictive subtype) is associated with a polymorphism in the novel norepinephrine transporter gene promoter polymorphic region Mol Psychiatry 7 2002 652 657
277. S. Matsushita, K. Suzuki, M. Murayama, N. Nishiguchi, A. Hishimoto, and A. Takeda Serotonin transporter regulatory region polymorphism is associated with anorexia nervosa Am J Med Genet B Neuropsychiatr Genet 128 2004 114 117
278. N.R. Wray, M.R. James, S.D. Gordon, T. Dumenil, L. Ryan, and W.L. Coventry Accurate, large-scale genotyping of 5HTTLPR and flanking single nucleotide polymorphisms in an association study of depression, anxiety, and personality measures Biol Psychiatry 66 2009 468 476
279. T.H. Wassink, H.C. Hazlett, E.A. Epping, S. Arndt, S.R. Dager, and G.D. Schellenberg Cerebral cortical gray matter overgrowth and functional variation of the serotonin transporter gene in autism Arch Gen Psychiatry 64 2007 709 717
280. M.R. Keikhaee, F. Fadai, M.R. Sargolzaee, A. Javanbakht, H. Najmabadi, and M. Ohadi Association analysis of the dopamine transporter (DAT1)-67A/T polymorphism in bipolar disorder Am J Med Genet B Neuropsychiatr Genet 135 2005 47 49
281. B.C. van Munster, S.E. de Rooij, M. Yazdanpanah, P.J. Tienari, K.H. Pitkl, and R.J. Osse The association of the dopamine transporter gene and the dopamine receptor 2 gene with delirium, a meta-analysis Am J Med Genet B Neuropsychiatr Genet 153B 2010 648 655
282. C. Dong, M.L. Wong, and J. Licinio Sequence variations of ABCB1, SLC6A2, SLC6A3, SLC6A4, CREB1, CRHR1 and NTRK2: association with major depression and antidepressant response in Mexican-Americans Mol Psychiatry 14 2009 1105 1118
283. S. Lpez-Len, A.C. Janssens, A.M. Gonzlez-Zuloeta Ladd, J. Del-Favero, and S.J. Claes Meta-analyses of genetic studies on major depressive disorder Mol Psychiatry 13 2008 772 785
284. N. Pattarachotanant, T. Sritharathikhun, S. Suttirat, and T. Tencomnao Association of C/T polymorphism in intron 14 of the dopamine transporter gene (rs40184) with major depression in a northeastern Thai population Genet Mol Res 9 2010 565 572
285. W. Min, T. Li, X. Ma, Z. Li, T. Yu, and D. Gao Monoamine transporter gene polymorphisms affect susceptibility to depression and predict antidepressant response Psychopharmacology (Berl) 205 2009 409 417
286. L. Christiansen, Q. Tan, M. Iachina, L. Bathum, T.A. Kruse, and M. McGue Candidate gene polymorphisms in the serotonergic pathway: influence on depression symptomatology in an elderly population Biol Psychiatry 61 2007 223 230
287. C. Guindalini, M. Howard, K. Haddley, R. Laranjeira, D. Collier, and N. Ammar A dopamine transporter gene functional variant associated with cocaine abuse in a Brazilian sample Proc Natl Acad Sci USA 103 2006 4552 4557
288. J. Gelernter, H.R. Kranzler, S.L. Satel, and P.A. Rao Genetic association between dopamine transporter protein alleles and cocaine-induced paranoia Neuropsychopharmacology 11 1994 195 200
289. A.M. Dlugos, A. Hamidovic, A.A. Palmer, and H. de Wit Further evidence of association between amphetamine response and SLC6A2 gene variants Psychopharmacology (Berl) 206 2009 501 511
290. A. Sikander, S.V. Rana, S.K. Sinha, K.K. Prasad, S.K. Arora, and S.K. Sharma Serotonin transporter promoter variant: analysis in Indian IBS patients and control population J Clin Gastroenterol 43 2009 957 961
291. S. Ulrich, M. Hersberger, M. Fischler, Y. Nussbaumer-Ochsner, U. Treder, and E.W. Russi Genetic polymorphisms of the serotonin transporter, but not the 2a receptor or nitric oxide synthetase, are associated with pulmonary hypertension in chronic obstructive pulmonary disease Respiration 79 2010 288 295
292. P. Ksiazek, K. Buraczynska, and M. Buraczynska Norepinephrine transporter gene (NET) polymorphism in patients with type 2 diabetes Kidney Blood Press Res 29 2006 338 343
293. M. Deuschle, M. Schredl, C. Schilling, S. Wst, J. Frank, and S.H. Witt Association between a serotonin transporter length polymorphism and primary insomnia Sleep 33 2010 343 347
294. S. Sen, M. Burmeister, and D. Ghosh Meta-analysis of the association between a serotonin transporter promoter polymorphism (5-HTTLPR) and anxiety-related personality traits Am J Med Genet B Neuropsychiatr Genet 127 2004 85 89
295. E. Voyiaziakis, O. Evgrafov, D. Li, H.J. Yoon, P. Tabares, and J. Samuels Association of SLC6A4 variants with obsessive-compulsive disorder in a large multicenter US family study Mol Psychiatry 2009 [Epub ahead of print]
296. J.R. Shannon, N.L. Flattem, J. Jordan, G. Jacob, B.K. Black, and I. Biaggioni Orthostatic intolerance and tachycardia associated with norepinephrine-transporter deficiency N Engl J Med 342 2000 541 549
297. R. Treister, D. Pud, R.P. Ebstein, E. Laiba, E. Gershon, and M. Haddad Associations between polymorphisms in dopamine neurotransmitter pathway genes and pain response in healthy humans Pain 147 2009 187 193
298. S.N. Kelada, H. Checkoway, S.L. Kardia, C.S. Carlson, P. Costa-Mallen, and D.L. Eaton 5′ and 3′ region variability in the dopamine transporter gene (SLC6A3), pesticide exposure and Parkinson's disease risk: a hypothesis-generating study Hum Mol Genet 15 2006 3055 3062
299. D. Albani, A. Vittori, S. Batelli, L. Polito, S. De Mauro, and D. Galimberti Serotonin transporter gene polymorphic element 5-HTTLPR increases the risk of sporadic Parkinson's disease in Italy Eur Neurol 62 2009 120 123
300. C.E. Glatt, A.D. Wahner, D.J. White, A. Ruiz-Linares, and B. Ritz Gain-of-function haplotypes in the vesicular monoamine transporter promoter are protective for Parkinson disease in women Hum Mol Genet 15 2006 299 305
301. H.J. Grabe, C. Spitzer, C. Schwahn, A. Marcinek, A. Frahnow, and S. Barnow Serotonin transporter gene (SLC6A4) promoter polymorphisms and the susceptibility to posttraumatic stress disorder in the general population Am J Psychiatry 166 2009 926 933
302. M.E. Talkowski, G. Kirov, M. Bamne, L. Georgieva, G. Torres, and H. Mansour A network of dopaminergic gene variations implicated as risk factors for schizophrenia Hum Mol Genet 17 2008 747 758
303. N.C. Allen, S. Bagade, M.B. McQueen, J.P. Ioannidis, F.K. Kavvoura, and M.J. Khoury Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database Nat Genet 40 2008 827 834
304. D.J. Vandenbergh, C.J. Bennett, M.D. Grant, A.A. Strasser, R. O'Connor, and R.L. Stauffer Smoking status and the human dopamine transporter variable number of tandem repeats (VNTR) polymorphism: failure to replicate and finding that never-smokers may be different Nicotine Tob Res 4 2002 333 340
305. P.Y. Lin, and G. Tsai Association between serotonin transporter gene promoter polymorphism and suicide: results of a meta-analysis Biol Psychiatry 55 2004 1023 1030
306. M.R. Munafo, T. Clark, and J. Flint Does measurement instrument moderate the association between the serotonin transporter gene and anxiety-related personality traits? A meta-analysis Mol Psychiatry 10 2005 415 419
307. L.J. Strug, R. Suresh, A.J. Fyer, A. Talati, P.B. Adams, and W. Li Panic disorder is associated with the serotonin transporter gene (SLC6A4) but not the promoter region (5-HTTLPR) Mol Psychiatry 15 2010 166 176
308. T.G. Noskova, A.V. Kazantseva, A.E. Gareeva, D.A. Gasina, S.U. Tuktarova, and E.K. Khusnutdinova [Association of several polymorphic loci of serotoninergic genes with unipolar depression] Genetika 45 2009 842 848
309. F.W. Lohoff, A.E. Weller, P.J. Bloch, R.J. Buono, G.A. Doyle, and T.N. Ferraro Association between polymorphisms in the vesicular monoamine transporter 1 gene (VMAT1/SLC18A1) on chromosome 8p and schizophrenia Neuropsychobiology 57 2008 55 60
310. M. Richards, Y. Iijima, H. Kondo, T. Shizuno, H. Hori, and K. Arima Association study of the vesicular monoamine transporter 1 (VMAT1) gene with schizophrenia in a Japanese population Behav Brain Funct 2 2006 39
311. F.W. Lohoff, J.P. Dahl, T.N. Ferraro, S.E. Arnold, J. Gallinat, and T. Sander Variations in the vesicular monoamine transporter 1 gene (VMAT1/SLC18A1) are associated with bipolar i disorder Neuropsychopharmacology 31 2006 2739 2747
312. J.S. Kooij, A.M. Boonstra, S.H. Vermeulen, A.G. Heister, H. Burger, and J.K. Buitelaar Response to methylphenidate in adults with ADHD is associated with a polymorphism in SLC6A3 (DAT1) Am J Med Genet B Neuropsychiatr Genet 147B 2008 201 208
313. R. Joober, N. Grizenko, S. Sengupta, L.B. Amor, N. Schmitz, and G. Schwartz Dopamine transporter 3′-UTR VNTR genotype and ADHD: a pharmaco-behavioural genetic study with methylphenidate Neuropsychopharmacology 32 2007 1370 1376
314. J. Kirchheiner, K. Nickchen, J. Sasse, M. Bauer, I. Roots, and J. Brockmller A 40-basepair VNTR polymorphism in the dopamine transporter (DAT1) gene and the rapid response to antidepressant treatment Pharmacogenomics J 7 2007 48 55
315. J.A. Stapleton, G. Sutherland, and C. O'Gara Association between dopamine transporter genotypes and smoking cessation: a meta-analysis Addict Biol 12 2007 221 226 (Pubitemid 46753645)
316. C. O'Gara, J. Stapleton, G. Sutherland, C. Guindalini, B. Neale, and G. Breen Dopamine transporter polymorphisms are associated with short-term response to smoking cessation treatment Pharmacogenet Genomics 17 2007 61 67
317. M. Xu, Q. Xing, S. Li, Y. Zheng, S. Wu, and R. Gao Pharmacogenetic effects of dopamine transporter gene polymorphisms on response to chlorpromazine and clozapine and on extrapyramidal syndrome in schizophrenia Prog Neuropsychopharmacol Biol Psychiatry 2010 34:102632
318. B. Franke, A.A. Vasquez, S. Johansson, M. Hoogman, J. Romanos, and A. Boreatti-Hmmer Multicenter analysis of the SLC6A3/DAT1 VNTR haplotype in persistent ADHD suggests differential involvement of the gene in childhood and persistent ADHD Neuropsychopharmacology 35 2010 656 664
319. P. Pal, M. Mihanovi, S. Molnar, H. Xi, G. Sun, and S. Guha Association of tagging single nucleotide polymorphisms on 8 candidate genes in dopaminergic pathway with schizophrenia in Croatian population Croat Med J 50 2009 361 369
320. A. Sieminska, K. Buczkowski, E. Jassem, M. Niedoszytko, and E. Tkacz Influences of polymorphic variants of DRD2 and SLC6A3 genes, and their combinations on smoking in Polish population BMC Med Genet 10 2009 92
321. P.A. Siz, M.P. Garca-Portilla, C. Arango, B. Morales, B. Arias, and P. Corcoran Genetic polymorphisms in the dopamine-2 receptor (DRD2), dopamine-3 receptor (DRD3), and dopamine transporter (SLC6A3) genes in schizophrenia: data from an association study Prog Neuropsychopharmacol Biol Psychiatry 34 2010 26 31
322. A.W. Bergen, D.V. Conti, D. Van Den Berg, W. Lee, J. Liu, and D. Li Dopamine genes and nicotine dependence in treatment-seeking and community smokers Neuropsychopharmacology 34 2009 2252 2264
323. S.S. Lee, A. Chronis-Tuscano, K. Keenan, W.E. Pelham, J. Loney, and C.A. Van Hulle Association of maternal dopamine transporter genotype with negative parenting: evidence for gene x environment interaction with child disruptive behavior Mol Psychiatry 15 2010 548 558
324. R.J. Neuman, E. Lobos, W. Reich, C.A. Henderson, L.W. Sun, and R.D. Todd Prenatal smoking exposure and dopaminergic genotypes interact to cause a severe ADHD subtype Biol Psychiatry 61 2007 1320 1328
325. W.G. Frankle, R. Narendran, Y. Huang, D.R. Hwang, I. Lombardo, and C. Cangiano Serotonin transporter availability in patients with Schizophrenia: a Positron Emission Tomography Imaging Study with [(11)C]DASB Biol Psychiatry 57 2005 1510 1516
326. K.Y. Little, D.P. McLaughlin, L. Zhang, C.S. Livermore, G.W. Dalack, and P.R. McFinton Cocaine, ethanol, and genotype effects on human midbrain serotonin transporter binding sites and mRNA levels Am J Psychiatry 155 1998 207 213
327. A. Heils, A. Teufel, S. Petri, G. Stober, P. Riederer, and D. Bengel Allelic variation of human serotonin transporter gene expression J Neurochem 66 1996 2621 2624
328. S. Eddahibi, M. Humbert, E. Fadel, B. Raffestin, M. Darmon, and F. Capron Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension J Clin Invest 108 2001 1141 1150
329. K.P. Lesch, D. Bengel, A. Heils, S.Z. Sabol, B.D. Greenberg, and S. Petri Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region Science 274 1996 1527 1531
330. C. Bonvicini, A. Minelli, C. Scassellati, M. Bortolomasi, M. Segala, and R. Sartori Serotonin transporter gene polymorphisms and treatment-resistant depression Prog Neuropsychopharmacol Biol Psychiatry 34 2010 934 939
331. W. Min, T. Li, X. Ma, Z. Li, T. Yu, and D. Gao Monoamine transporter gene polymorphisms affect susceptibility to depression and predict antidepressant response Psychopharmacology (Berl) 205 2009 409 417
332. K.C. Koenen, A.E. Aiello, E. Bakshis, A.B. Amstadter, K.J. Ruggiero, and R. Acierno Modification of the association between serotonin transporter genotype and risk of posttraumatic stress disorder in adults by county-level social environment Am J Epidemiol 169 2009 704 711
333. D.A. Mrazek, A.J. Rush, J.M. Biernacka, D.J. O'Kane, J.M. Cunningham, and E.D. Wieben SLC6A4 variation and citalopram response Am J Med Genet B Neuropsychiatr Genet 150B 2009 341 351
334. X.Z. Hu, A.J. Rush, D. Charney, A.F. Wilson, A.J. Sorant, and G.J. Papanicolaou Association between a functional serotonin transporter promoter polymorphism and citalopram treatment in adult outpatients with major depression Arch Gen Psychiatry 64 2007 783 792
335. M.J. Wilkie, G. Smith, R.K. Day, K. Matthews, D. Smith, and D. Blackwood Polymorphisms in the SLC6A4 and HTR2A genes influence treatment outcome following antidepressant therapy Pharmacogenomics J 9 2009 61 70
336. C. Otte, J. McCaffery, S. Ali, and M.A. Whooley Association of a serotonin transporter polymorphism (5-HTTLPR) with depression, perceived stress, and norepinephrine in patients with coronary disease: the Heart and Soul Study Am J Psychiatry 164 2007 1379 1384
337. R. Mssner, A. Henneberg, A. Schmitt, Y.V. Syagailo, M. Grssle, and T. Hennig Allelic variation of serotonin transporter expression is associated with depression in Parkinson's disease Mol Psychiatry 6 2001 350 352
338. J. Lasky-Su, B.M. Neale, B. Franke, R.J. Anney, K. Zhou, and J.B. Maller Genome-wide association scan of quantitative traits for attention deficit hyperactivity disorder identifies novel associations and confirms candidate gene associations Am J Med Genet B Neuropsychiatr Genet 147B 2008 1345 1354
339. E. Mick, B. Neale, F.A. Middleton, J.J. McGough, and S.V. Faraone Genome-wide association study of response to methylphenidate in 187 children with attention-deficit/hyperactivity disorder Am J Med Genet B Neuropsychiatr Genet 147B 2008 1412 1418
340. K.Y. Little, D.M. Krolewski, L. Zhang, and B.J. Cassin Loss of striatal vesicular monoamine transporter protein (VMAT2) in human cocaine users Am J Psychiatry 160 2003 47 55
341. S. Gilman, R.A. Koeppe, K.M. Adams, L. Junck, K.J. Kluin, and D. Johnson-Greene Decreased striatal monoaminergic terminals in severe chronic alcoholism demonstrated with (+)[11C]dihydrotetrabenazine and positron emission tomography Ann Neurol 44 1998 326 333
342. S.R. Hansson, B.J. Hoffman, and E. Mezey Ontogeny of vesicular monoamine transporter mRNAs VMAT1 and VMAT2. I. The developing rat central nervous system Brain Res Dev Brain Res 110 1998 135 158
343. N.A. Buckley, and P.R. McManus Fatal toxicity of serotoninergic and other antidepressant drugs: analysis of United Kingdom mortality data Br Med J 325 2003 1332 1333
344. S.K. Kulkarni, and A. Dhir Current investigational drugs for major depression Expert Opin Investig 18 2009 767 788
345. A.F. Schatzberg Pharmacological principles of antidepressant efficacy Hum Psychopharmacol 17 2002 S17 S22
346. M.B. Youdim, and M. Weinstock Therapeutic applications of selective and non-selective inhibitors of monoamine oxidase A and B that do not cause significant tyramine potentiation Neurotoxicology 25 2004 243 250
347. L.V. Kessing, M.G. Hansen, P.K. Andersen, and J. Angst The predictive effect of episodes on the risk of recurrence in depressive and bipolar disorders-a life-long perspective Acta Psychiatria Scandinavian 109 2004 339 344
348. R.J. Baldessarini, S.N. Ghaemi, and A.C. Viguera Tolerance in antidepressant treatment Psychother Psychosom 71 2002 177 179
349. D. Mischoulon, G. Opitz, K. Kelly, M. Fava, and J. Rosenbaum A preliminary open study of the tolerability and effectiveness of Nefazodone in major depressive disorder: comparing patients who recently discontinued an SSRI with those on no recent antidepressant treatment Depress Anxiety 19 2004 43 50
350. H.G. Ruh, J. Huyser, J.A. Swinkels, and A.H. Schene Switching antidepressants after a first selective serotonin reuptake inhibitor in major depressive disorder: a systematic review J Clin Psychiatry 67 2006 1836 1855 (Pubitemid 46055194)
351. T.M. Pundiak, B.G. Case, E.D. Peselow, and L. Mulcare Discontinuation of maintenance selective serotonin reuptake inhibitor monotherapy after 5 years of stable response: a naturalistic study J Clin Psychiatry 69 2008 1811 1817
352. M.T. Pato, J.L. Hill, and D.L. Murphy A clomipramine dosage reduction study in the course of long-term treatment of obsessive-compulsive disorder patients Psychopharmacol Bull 26 1990 211 214
353. S.P. Runyon, and F.I. Carroll Dopamine transporter ligands: recent developments and therapeutic potential Curr Top Med Chem 6 2006 1825 1843